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Abstract
Objectives: The role of serum a-fetoprotein (AFP) measurements in the diagnosis of hepatocellular
carcinoma (HCC) remains controversial. Some guidelines have advised against the use of AFP in the
diagnosis of HCC. This study was conducted to evaluate the performance of AFP in the diagnosis of HCC,
and to identify the optimal cut-off value of serum AFP in the diagnosis of HCC in patients with a hepatic
mass.
Methods: Patients who presented during the period from May 1997 to March 2003 with hepatic lesions,
for whom paired data on serum AFP values at baseline and lesion histology were available, were
reviewed. The performance of AFP in the diagnosis of HCC was determined using receiver operating
characteristic curve analysis.
Results: Data for a total of 805 patients were evaluated. The mean AFP value was 26 900 ng/ml (range:
0–1 965 461 ng/ml). The histological diagnosis was HCC in 557 patients. The optimal AFP cut-off value
was 10 ng/ml (for sensitivity of 82.6% and specificity of 70.4%). At a cut-off level of 200 ng/ml, sensitivity,
specificity, and positive and negative predictive values were 47.7%, 97.1%, 97.5% and 44.4%, respec-
tively. The diagnostic performance of AFP remains similar in patients with chronic hepatitis B virus
infection, despite a lower negative predictive value. Common aetiologies of liver lesions associated with
elevated AFP include cholangiocarcinoma and neuroendocrine tumours.
Conclusions: In Asian patients with suspicious liver lesions, the cut-off AFP level of 200 ng/ml is useful
to achieve a diagnosis of HCC with high specificity and reasonable sensitivity. The measurement of serum
AFP should not be excluded from guidelines for the diagnosis of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer and the third leading cause of cancer-related death glo-
bally.1,2 A number of different methodologies exist for the diag-
nosis of HCC. Histological evidence used to be considered as the
reference standard, but the biopsy procedure is hampered by con-
cerns for bleeding complications in patients with co-morbid cir-
rhosis. Recent clinical practice has shifted its emphasis to the
identification of typical patterns of contrast enhancement on
dynamic imaging in the diagnosis of HCC.3–6 However, it is not
uncommon to encounter patients whose hepatic lesions do not
demonstrate typical patterns. It has been estimated that >30% of
HCCs do not exhibit the radiological features regarded as ‘typical’
on dynamic contrast imaging.7,8 For hepatic tumours without
typical radiological features, biopsy is still recommended in most
international guidelines.3–5
In addition to the radiological methodology, clinicians fre-
quently measure serum a-fetoprotein (AFP) during the workup
of hepatic lesions. Serum AFP is elevated in 60–80% of patients
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with HCC, and is useful in screening and monitoring the treat-
ment responses of HCC.9–12 However, serum AFP values are influ-
enced by non-neoplastic factors, such as the presence of viral
hepatitis or cirrhosis. Therefore, a cut-off value is required to
improve specificity in the diagnosis of HCC. At present, the clini-
cal use and optimal cut-off level of serum AFP in the diagnosis of
HCC remain controversial. The American Association for the
Study of Liver Disease (AASLD) guideline of 2005 recommends
the use of an AFP value of 200 ng/ml as the cut-off level for the
diagnosis of HCC.3 However, in a subsequent updated version of
the AASLD guideline, this recommendation on the diagnostic use
of AFP has been removed because of concern over false positivity.4
By contrast, European and Asian Pacific guidelines continue to
recommend the use of an AFP level of 200 ng/ml as a reliable
cut-off for the diagnosis of HCC.5,6
At the present centre, prior to the implementation of non-
invasive diagnostic guidelines, histology was considered to repre-
sent the reference standard method of achieving a diagnosis of
HCC. As a result, patients with inoperable HCC or suspicious
hepatic lesions were subjected to liver biopsy in order to confirm
the diagnosis. The current study was conducted to allow a retro-
spective review of baseline serum AFP values in patients who
underwent hepatectomy or a percutaneous needle biopsy of a
hepatic lesion. The aims of the study were: (i) to study the per-
formance of AFP in the diagnosis of HCC, and (ii) to identify the
optimal AFP cut-off value for the diagnosis of HCC in patients
who present with a hepatic mass.
Materials and methods
Study design
This was a retrospective study conducted to review the level
of serum AFP at baseline and correlate it with the final histo-
logical diagnosis. The study was reported according to the
STARD (STAndards for the Reporting of Diagnostic accuracy)
guidelines.13
Study population
The study population was composed of consecutive patients who
presented at the study centre with liver lesions from May 1997 to
March 2003. All patients were managed in either the hepatobiliary
surgical unit or the joint hepatoma clinic in the hospital; the latter
is a multidisciplinary clinic that includes surgeons, oncologists
and radiologists. Inclusion criteria were: (i) presence of one or
more focal liver lesions depicted on ultrasonography or computed
tomography of the abdomen; (ii) availability of a histological
diagnosis of the corresponding liver lesion(s) obtained by resec-
tion or percutaneous needle biopsy; (iii) availability of data on the
serumAFP concentration within 1 month of the histological diag-
nosis and before the commencement of any treatment for cancer,
and (iv) a patient age of18 years. Patients with chronic hepatitis
B virus (HBV) infection were identified according to positive
results for hepatitis B surface antigen (HBsAg) for 6 months.
Chronic hepatitis C virus (HCV) infection was indicated by the
detection of HCV RNA persisting for >6 months. The study was
approved by the institutional review board of the Chinese Univer-
sity of Hong Kong.
Histological diagnosis
Ultrasound-guided percutaneous biopsy was performed in single
lesions or in the most suspicious of multiple lesions with one or
two passes of an 18-gauge automated biopsy gun (Temno®; Car-
dinal Health, Inc., McGaw Park, IL, USA). The quality of biopsy
was examined by a radiologist immediately after the procedure to
ascertain that a good tissue core had been obtained. The biopsy
was sent to the pathologist for histological examination. If a lesion
was diagnosed histologically as non-tumorous or as representing a
benign condition, an additional 2-year period of clinical and
radiological follow-up was initiated. A diagnosis of a benign con-
dition was considered definitive if there was no change in clinical
and radiological outcomes in the 2-year follow-up. Any results of
repeated biopsies during the 2-year period were reviewed to
ensure the hepatic lesion was not malignant.
Quantification of level of AFP
SerumAFP concentration was measured by electrochemilumines-
cence immunoassay (E170 Analytics; Roche Diagnostics Corp.,
Indianapolis, IN, USA). The adult reference interval for serum
AFP was <7 ng/ml and the coefficient of variation was 5%
across the linear range (1–1210 ng/ml) of measurement. Labora-
tory staff involved in the measurement of AFP were unaware of
final histological diagnoses. SerumAFPmeasured within 1 month
prior to the histological diagnosis was reviewed. If more than one
AFP measurement was recorded during this period, the level
measured at the time-point closest to the histological diagnosis
was chosen for analysis in the current study.
Statistical analysis
Continuous variables were expressed as the mean  standard
deviation. The sensitivity and specificity of serum AFP in the
diagnosis of HCC in the whole study population and in the HBV-
infected subgroup were analysed. Receiver operating characteristic
(ROC) analysis using the area under the curve (AUC) was
employed to identify the optimal threshold of any serumAFP level
for the diagnosis of HCC by giving equal weighting to sensitivity
and specificity. The sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV) and accuracy of optimal
thresholds were calculated. The value of the AUC and the corre-
sponding 95% confidence interval (CI) were calculated and the
significance of these thresholds re-evaluated using the chi-squared
test or Fisher’s exact test. Various cut-off values for the diagnosis
of HCC were determined based on different criteria. Subgroup
analyses were determined for the whole population, the HBV-
infected population, and patients submitted to hepatectomy or
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percutaneous needle biopsy, respectively. Statistical analyses were
performed using sas Version 8.2 (SAS Institute, Inc., Cary, NC,
USA).
Results
Baseline characteristics
The study was commenced in August 2012 and completed in
October 2012. A total of 805 patients were recruited in this study.
Their baseline characteristics are summarized in Table 1. Their
mean age was 55.9 years and 633 (78.6%) were male.A total of 563
(69.9%) patients were positive for HBsAg. Six patients had
chronic HCV infection and five of these had concomitant HBV
infection. The mean AFP value was 26 900 ng/ml (range:
0–1 965 461 ng/ml). Serum AFP was higher in HBV-infected
patients than in patients without HBV infection (33 956 ng/ml
versus 10 485 ng/ml; P = 0.013). Histological diagnoses indicated
HCC in 557 patients.Histological indications of non-HCC disease
are listed in Table 1. Common non-HCC histology included sec-
ondary liver disease, adenocarcinoma of unknown origin and cir-
rhosis or chronic hepatitis.
Performance of serum AFP in the diagnosis of HCC
The accuracy of serum AFP in predicting the diagnosis of HCC in
patients with hepatic lesions was evaluated using ROC analyses
(Table 2) and the AUC (Fig. 1). In the whole cohort (n = 805), the
accuracy of AFP in the diagnosis of HCC produced an AUC of
0.83 (95% CI 0.81–0.86). The optimal cut-off AFP value was
10 ng/ml, at which sensitivity, specificity, PPV and NPV were
82.6%, 70.4%, 86.6% and 63.6%, respectively. At the conventional
cut-off value of 200 ng/ml, sensitivity, specificity, PPV and NPV
were 47.7%, 97.1%, 97.5% and 44.4%, respectively. For a definitive
diagnosis of HCC (i.e. 100% specificity and PPV), the cut-off
value was 500 ng/ml, with corresponding sensitivity and NPV of
38.1% and 41.1%, respectively.
Performance of serum AFP in the diagnosis of HCC in
HBV-infected patients
Subgroup analysis of the performance of AFP was conducted in
patients with chronic HBV infection (Table 3). Five of the 563
patients with chronic HBV infection had concomitant HCV
infection and were excluded from this analysis. In this subgroup
(n = 558), the AUC for the accuracy of AFP in the diagnosis of
HCC was 0.77 (95% CI 0.73–0.81) (Fig. 2). The optimal cut-off
value of AFP was 10 ng/ml, at which sensitivity, specificity, PPV
and NPV were 85.1%, 42.7%, 88.7% and 35.2%, respectively. At
a cut-off level of 200 ng/ml, sensitivity and specificity were
49.5% and 95.5%, respectively, and the PPV and NPV were
98.4% and 27.3%, respectively. To achieve a definitive diagnosis
of HCC (i.e. 100% specificity and PPV), the cut-off value was
400 ng/ml, at which sensitivity and NPV were 41.2% and 24.4%,
respectively.
Table 1 Baseline characteristics and histological diagnoses in the
study cohort (n = 805)
Variable Value
Age, years, mean  SD 55.9  12
Sex, male : female 632:173
Specimen, n
Biopsy of hepatic mass 636
Hepatectomy sample 169
HBsAg-positive, n 563
HCV-positive, n 6
AFP, ng/ml
Mean  SD 26 900  142 850
Range 0–1 965 461
Log AFP, ng/ml
Mean  SD 1.975  1.486
Range -0.1 to 6.293
Histological diagnosis, n
Hepatocellular carcinoma 557
Cirrhosis/chronic hepatitis 41
Metastasis 79
Colon (n = 48)
Stomach (n = 15)
Breast (n = 4)
Cervix (n = 2)
Nasopharynx (n = 3)
Lung (n = 7)
Cholangiocarcinoma 19
Adenomatous hyperplasia 7
Haemangioma 20
Fatty change 4
Granulomatous reaction 8
Sarcoma 2
Abscess 3
Adenocarcinoma 36
Non-pathological diagnosis 3
Regenerative nodule 7
Amyloidosis 1
Cystadenoma 2
Adenoma 3
Focal nodular hyperplasia 3
Neuroendocrine tumour 4
Haemangiopericytoma 1
Atypia 1
Angiomyolipoma 1
Hepatoblastoma 1
Leiomyosarcoma 2
SD, standard deviation; HBsAg, hepatitis B surface antigen; HCV, hepa-
titis C virus; AFP, a-fetoprotein.
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Performance of serum AFP in the diagnosis of HCC in
patients submitted to hepatectomy or biopsy
The accuracy of AFP was also analysed in the subgroups of
patients submitted to hepatectomy and percutaneous needle
biopsy, respectively (Table 4). The optimal cut-off values in the
hepatectomy (n = 169) and biopsy (n = 636) subgroups were
5 ng/ml and 10 ng/ml, respectively. At the conventional cut-off of
200 ng/ml, specificity was similar between the two groups,
whereas sensitivity was lower in the hepatectomy (35.2%) than the
biopsy (51.3%) subgroup. Definitive diagnostic cut-off levels (i.e.
to achieve 100% specificity) were 400 ng/ml and 500 ng/ml in the
hepatectomy and biopsy subgroups, respectively.
Histological diagnosis in patients with AFP
of >200 ng/ml
Among the patients without chronic HBV infection were five
patients in whom histological diagnosis did not indicate HCC but
in whom AFP values higher than the conventional cut-off of
200 ng/ml were established. Three of these patients were found to
have histologically confirmed cholangiocarcinoma; AFP values in
these patients were 489 ng/ml, 307 ng/ml and 233 ng/ml, respec-
tively. The fourth patient was found to have a neuroendocrine
tumour (AFP = 307 ng/ml) and the fifth had a histological diag-
nosis of liver metastases of gastric cancer origin (AFP = 272 ng/
ml). Among the patients with chronic HBV infection, two patients
without HCC had AFP values of >200 ng/ml. Their respective
diagnoses were adenocarcinoma of unknown origin (AFP =
298 ng/ml) and neuroendocrine tumour (AFP = 365 ng/ml).
Discussion
The patient cohort (n = 805) in the current study was character-
ized by the availability of histological evidence of hepatic lesions
and data on serum AFP at diagnosis. These features enabled the
study of the performance of AFP in the diagnosis of HCC in
patients with hepatic lesions. The results have generated two
important findings that pertain to the establishing of an optimum
cut-off value of serum AFP for the diagnosis of HCC. Firstly, if
both sensitivity and specificity are considered, the optimal cut-off
is 10 ng/ml. Secondly, the conventional AFP cut-off value of
200 ng/ml is associated with satisfactory specificity and PPV (i.e.
low false positivity) of >97%, but at a cost of lower sensitivity and
NPV. The former cut-off is more important for the surveillance of
HCC in patients without any hepatic lesions or symptoms. In the
workup of a patient with a hepatic lesion(s), the cut-off of
200 ng/ml should be considered more relevant because a diagno-
sis of HCC can be regarded with substantial confidence when the
AFP value is higher than the cut-off value. Although the cut-off
value of 500 ng/ml proved able to contribute to a definitive diag-
nosis of HCC with 100% specificity and PPV in the current study,
its lower range of sensitivity limits its widespread use in the clini-
cal setting.
Most recent international guidelines recommend the use of
dynamic imaging to characterize the vascular pattern of a liver
Table 2 Whole-cohort (n = 805) analysis: a-fetoprotein (AFP) thresholds obtained from receiver operating characteristic curves by various
criteria to predict hepatocellular carcinoma
Parameters Optimal Se and Sp Conventional cut-off 100% Sp
AFP cut-off level 10 ng/ml 200 ng/ml 500 ng/ml
True positives, n 464 268 214
False positives, n 72 7 0
True negatives, n 171 236 243
False negatives, n 98 294 348
Sensitivity 82.6% 47.7% 38.1%
Specificity 70.4% 97.1% 100%
PPV 86.6% 97.5% 100%
NPV 63.6% 44.4% 41.1%
Accuracy 78.9% 62.6% 56.8%
Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.
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Figure 1 Receiver operating characteristic (ROC) curve showing the
sensitivity and specificity of serum a-fetoprotein (AFP) values in the
diagnosis of hepatocellular carcinoma in the entire cohort (n = 805).
Area under the curve: 0.83 (95% confidence interval 0.81–0.86)
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lesion.4,6 However, in clinical practice, it is not uncommon to
encounter patients in whom liver lesions do not demonstrate
typical contrast enhancement in the arterial phase and washout in
the portovenous phase. According to two Asian series, typical
enhancement features may be absent in 30–60% of HCC cases.7,8
In addition, it has been suggested that poorly differentiated HCC
is associated with an atypical pattern of enhancement, and infil-
trative or diffuse HCC may have very subtle radiological fea-
tures.14 Under such circumstances, it will be extremely difficult for
clinicians to achieve a diagnosis of HCC based on radiological
evidence alone.15,16 The current study provides evidence that the
AFP value may assist clinicians in diagnosing HCC in a propor-
tion of patients. This may help to avoid biopsy procedures in
patients who are at risk for developing complications from the
procedure.
In the current study, the sensitivity and specificity of AFP in the
diagnosis of HCC was comparable with data reported in the
literature.17–19 However, it should be noted that the PPV observed
in the current study is higher than levels reported in other HCC
screening studies.17–19 This is most probably because the patient
cohort in the current study consisted of patients with suspected
liver lesions on imaging which warranted biopsy or surgery. As a
result, the prevalence of HCC in the current cohort can be
expected to be higher than that in a patient population without
suspicious liver lesions(s) and this will reduce the false positivity
rate and lead to a higher PPV. This observation highlights the fact
that an elevation in serum AFP is more informative in the setting
of workup in patients with a high index of suspicion, such as in
patients in whom the presence of symptoms or liver lesions is
known, rather than in the setting of surveillance for HCC in
asymptomatic patients.
Infection by HBV accounts for >80% of HCC in endemic
regions, including Asia and sub-Saharan Africa.20 Not surpris-
ingly, the present cohort was characterized by a high proportion of
patients with chronic HBV infection. The influence of HBV infec-
tion on the performance of AFP in the diagnosis of HCC has been
studied mainly in surveillance cohorts, from which variable con-
clusions have been obtained.17,21–24 In the current study, the per-
formance of AFP in a subgroup of patients with chronic HBV
infection was determined. The results showed that although the
PPVs in the HBV-infected subgroup and the whole cohort were
grossly similar, the NPVs were significantly lower in the HBV-
infected subgroup. Even at the low cut-off value of 10 ng/ml, the
NPV value in the HBV-infected subgroup was only 35.2%,
whereas that in the entire cohort was 63.6%. The likely cause of
this dissimilarity is that a large proportion of non-HCC cases
in the cohort occur in patients without HBV infection and this
contributes to the higher number of true negative cases in the
whole-cohort analysis. By focusing analysis on HBV-infected
populations, the proportion of true negative cases will be signifi-
cantly diminished, resulting in a lower NPV. This finding has
Table 3 Subgroup analysis of patients with chronic hepatitis B virus (HBV) infection (n = 563): a-fetoprotein (AFP) thresholds obtained from
receiver operating characteristic curves by various criteria to predict hepatocellular carcinoma
Parameters Optimal Se and Sp Conventional cut-off 100% Sp
AFP cut-off level 10 ng/ml 200 ng/ml 400 ng/ml
True positives, n 399 232 193
False positives, n 51 2 0
True negatives, n 38 87 89
False negatives, n 70 237 276
Sensitivity 85.1% 49.5% 41.2%
Specificity 42.7% 97.8% 100%
PPV 88.7% 99.1% 100%
NPV 35.2% 26.9% 24.4%
Accuracy 78.3% 57.2% 50.5%
Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.
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Figure 2 Receiver operating characteristic (ROC) curve showing the
sensitivity and specificity of serum a-fetoprotein (AFP) values in the
subgroup of patients with chronic hepatitis B infection (n = 563).
Area under the curve: 0.77 (95% confidence interval 0.73–0.81)
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highlighted the limitation of AFP: although an elevation in AFP
raises the suspicion of HCC in patients with chronic HBV infec-
tion, the clinician should not be falsely reassured by an AFP value
lower than the cut-off level in these patients.
The current study also set out to determine the aetiologies of
AFP elevation in non-HCC cases. Cholangiocarcinoma and neu-
roendocrine tumours emerged as the tumour types most com-
monly associated with an elevation in AFP to >200 ng/ml. To
reduce the chance of a false positive finding, a number of devel-
opments have been made to improve the specificity of serum
markers for the diagnosis of HCC. The most notable of these are
the AFP Lens culinaris agglutinin reactive (AFP-L3) and the pro-
thrombin induced by the absence of vitamin K or antagonist II
(PIVKA-II). AFP-L3 is a fucosylated fraction of AFP that has been
reported to be more specific for the diagnosis of HCC.At a cut-off
value of 10%, AFP-L3 has specificity of >90% and sensitivity of
about 40%.25–28 PIVKA-II is an abnormal prothrombin found in
50–60% of patients with HCC.29–32 At a cut-off value of 40 mAU/
ml, the performance of PIVKA-II is similar to that of AFP and
achieves sensitivity of around 50% and specificity of 80–90%.29–32
PIVKA-II may be particularly useful in low or negative AFP cases
because its level is not correlated with AFP.33 The combination of
these two additional markers may help to improve the accuracy of
diagnosis of HCC.
The present study is subject to some limitations. Firstly, this was
a retrospective study and its results are subject to selection bias.
The authors aim to minimize this problem by recruiting a con-
secutive cohort of patients so that a more representative popula-
tion can be analysed. However, the AFP values and histological
diagnoses were objective findings, which were less subject to bias
by investigators’ interpretations. Secondly, dynamic contrast
imaging was not available in most patients. Therefore, it was not
feasible to correlate the radiological features of contrast imaging
with serum AFP values in this study. Thirdly, some tumour-
related information, such as details of tumour size or stage, was
not available in the cohort, which rendered subgroup analyses of
the performance of AFP according to tumour size or stage unfea-
sible. However, subgroup analyses were conducted in subgroups
of patients submitted to hepatectomy and biopsy, respectively, and
the results of these show that serum AFP measurements are con-
sistently specific for the diagnosis of HCC in these groups of
patients.
In conclusion, in Asian patients with suspicious liver lesions,
serum levels of AFP are useful to achieve the diagnosis of HCC.
The use of an AFP cut-off value of 200 ng/ml may help clinicians
to achieve a diagnosis with high specificity and reasonable sen-
sitivity. Such characteristics of AFP remain in patients with
chronic HBV infection. Data from the current study suggest that
Table 4 Subgroup analysis of patients submitted to hepatectomy (n = 169) or biopsy (n = 636): a-fetoprotein (AFP) thresholds obtained from
receiver operating characteristic curves by various criteria to predict hepatocellular carcinoma
Parameters Optimal Se and Sp Conventional cut-off 100% Sp
Hepatectomy group
AFP cut-off level 5 ng/ml 200 ng/ml 400 ng/ml
True positives, n 105 44 32
False positives, n 17 1 0
True negatives, n 27 43 44
False negatives, n 20 79 93
Sensitivity 84.0% 35.2% 25.6%
Specificity 61.4% 97.7% 100%
PPV 85.1% 97.8% 100%
NPV 57.4% 34.7% 32.1%
Accuracy 78.1% 51.5% 45.0%
Biopsy group
AFP cut-off level 10 ng/ml 200 ng/ml 500 ng/ml
True positives, n 378 224 186
False positives, n 64 6 0
True negatives, n 135 193 199
False negatives, n 59 213 251
Sensitivity 86.5% 51.3% 42.6%
Specificity 67.8% 97.0% 100%
PPV 85.5% 97.4% 100%
NPV 69.6% 47.5% 44.2%
Accuracy 80.7% 65.6% 60.5%
Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.
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the measurement of serum AFP should not be excluded from
guidelines for the diagnosis of HCC.
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